OBJECTIVE: To compare coronary artery calcium (CAC) progression between 2 treatment groups, pioglitazone versus glimepiride. METHODS AND RESULTS: The CHICAGO (Carotid Intima-Media Thickness in Atherosclerosis Using Pioglitazone) study demonstrated that pioglitazone significantly decreased carotid intima-media thickness progression compared with glimepiride in patients with type 2 diabetes mellitus. The CAC level was determined at baseline and at the end of 72 weeks of treatment in the pioglitazone (n=146) and glimepiride (n=153) treatment groups using electron beam computed tomography. There was no difference in CAC progression between the treatment groups. By using backward and forward selection models, age, race/ethnicity, and baseline apolipoprotein B level predicted CAC progression. There was no relationship between carotid intima-media thickness and CAC progression during the study. CONCLUSIONS: There was no difference in CAC progression in patients with type 2 diabetes mellitus treated with pioglitazone or glimepiride. Age, race/ethnicity, and baseline apolipoprotein B level predicted CAC progression in patients with type 2 diabetes mellitus.
RCT Entities:
OBJECTIVE: To compare coronary artery calcium (CAC) progression between 2 treatment groups, pioglitazone versus glimepiride. METHODS AND RESULTS: The CHICAGO (Carotid Intima-Media Thickness in Atherosclerosis Using Pioglitazone) study demonstrated that pioglitazone significantly decreased carotid intima-media thickness progression compared with glimepiride in patients with type 2 diabetes mellitus. The CAC level was determined at baseline and at the end of 72 weeks of treatment in the pioglitazone (n=146) and glimepiride (n=153) treatment groups using electron beam computed tomography. There was no difference in CAC progression between the treatment groups. By using backward and forward selection models, age, race/ethnicity, and baseline apolipoprotein B level predicted CAC progression. There was no relationship between carotid intima-media thickness and CAC progression during the study. CONCLUSIONS: There was no difference in CAC progression in patients with type 2 diabetes mellitus treated with pioglitazone or glimepiride. Age, race/ethnicity, and baseline apolipoprotein B level predicted CAC progression in patients with type 2 diabetes mellitus.
Authors: Ana V Diez Roux; Robert Detrano; Sharon Jackson; David R Jacobs; Pamela J Schreiner; Steven Shea; Moyses Szklo Journal: Circulation Date: 2005-09-06 Impact factor: 29.690
Authors: Theodore Mazzone; Peter M Meyer; George T Kondos; Michael H Davidson; Steven B Feinstein; Ralph B D'Agostino; Alfonso Perez; Steven M Haffner Journal: Diabetes Date: 2007-03 Impact factor: 9.461
Authors: A D Guerci; L A Spadaro; J J Popma; K J Goodman; B H Brundage; M Budoff; G Lerner; R F Vizza Journal: Am J Cardiol Date: 1997-01-15 Impact factor: 2.778
Authors: John A Dormandy; Bernard Charbonnel; David J A Eckland; Erland Erdmann; Massimo Massi-Benedetti; Ian K Moules; Allan M Skene; Meng H Tan; Pierre J Lefèbvre; Gordon D Murray; Eberhard Standl; Robert G Wilcox; Lars Wilhelmsen; John Betteridge; Kåre Birkeland; Alain Golay; Robert J Heine; László Korányi; Markku Laakso; Marián Mokán; Antanas Norkus; Valdis Pirags; Toomas Podar; André Scheen; Werner Scherbaum; Guntram Schernthaner; Ole Schmitz; Jan Skrha; Ulf Smith; Jan Taton Journal: Lancet Date: 2005-10-08 Impact factor: 79.321
Authors: Matthew J Budoff; Khurram Nasir; Songshou Mao; Philip H Tseng; Alex Chau; Sandy T Liu; Ferdinand Flores; Roger S Blumenthal Journal: Atherosclerosis Date: 2005-10-21 Impact factor: 5.162
Authors: Theodore Mazzone; Peter M Meyer; Steven B Feinstein; Michael H Davidson; George T Kondos; Ralph B D'Agostino; Alfonso Perez; Jean-Claude Provost; Steven M Haffner Journal: JAMA Date: 2006-11-13 Impact factor: 56.272
Authors: Erland Erdmann; John A Dormandy; Bernard Charbonnel; Massimo Massi-Benedetti; Ian K Moules; Allan M Skene Journal: J Am Coll Cardiol Date: 2007-04-16 Impact factor: 24.094
Authors: Richard A Kronmal; Robyn L McClelland; Robert Detrano; Steven Shea; João A Lima; Mary Cushman; Diane E Bild; Gregory L Burke Journal: Circulation Date: 2007-05-14 Impact factor: 29.690
Authors: Saul M Genuth; Helen Vlachos; Maria Mori Brooks; John P Bantle; Bernard R Chaitman; Jennifer Green; Sheryl F Kelsey; Spencer B King; Robert McBane; Edward Y Sako; David J Schneider; Michael Steffes; Robert L Frye Journal: Mayo Clin Proc Date: 2019-10-04 Impact factor: 7.616